AMNEAL PHARMACEUTICALS INC. - CLASS A COMMON STOC

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

22 12 2025 16:01:00 提供 Nasdaq GlobeNewswire

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

09 12 2025 16:01:00 提供 Nasdaq GlobeNewswire

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

05 12 2025 08:00:00 提供 Nasdaq GlobeNewswire

Amneal to Participate in Upcoming Investor Conferences

02 12 2025 08:00:01 提供 Nasdaq GlobeNewswire

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

02 12 2025 08:00:00 提供 Nasdaq GlobeNewswire

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

01 12 2025 16:01:00 提供 Nasdaq GlobeNewswire

Amneal Receives U.S. FDA Approval for Iohexol Injection

13 11 2025 16:01:00 提供 Nasdaq GlobeNewswire

Amneal Reports Third Quarter 2025 Financial Results

30 10 2025 06:00:01 提供 Nasdaq GlobeNewswire

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

29 10 2025 17:29:29 提供 Nasdaq GlobeNewswire

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

27 10 2025 08:00:00 提供 Nasdaq GlobeNewswire

Amneal to Report Third Quarter 2025 Results on October 30, 2025

30 9 2025 16:05:00 提供 Nasdaq GlobeNewswire

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

26 9 2025 08:00:00 提供 Nasdaq GlobeNewswire

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

23 9 2025 08:00:01 提供 Nasdaq GlobeNewswire

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

11 9 2025 08:00:00 提供 Nasdaq GlobeNewswire

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

04 9 2025 16:01:00 提供 Nasdaq GlobeNewswire

Amneal Reports Second Quarter 2025 Financial Results

05 8 2025 06:00:01 提供 Nasdaq GlobeNewswire

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

21 7 2025 07:39:02 提供 Nasdaq GlobeNewswire

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

21 7 2025 07:38:38 提供 Nasdaq GlobeNewswire

Amneal to Report Second Quarter 2025 Results on August 5, 2025

09 7 2025 08:00:00 提供 Nasdaq GlobeNewswire

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

25 6 2025 08:00:00 提供 Nasdaq GlobeNewswire